- Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma +12008 | Faculty of Medicine in Hradec Králové
- Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma +12008 | First Faculty of Medicine
- Allo-SCT using BU, CY and melphalan for children with AML in second CR2013 | Second Faculty of Medicine
- The variance of melphalan doses related to kilogram of body weight and the consequences2010 | Central Library of Charles University
- The variance of melphalan doses related to kilogram of body weight and the consequences2010 | Faculty of Medicine in Pilsen
- Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma2009 | First Faculty of Medicine
- Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma2011 | First Faculty of Medicine
- High-Dose Treosulfan and Melphalan as Consolidation Therapy Versus Standard Therapy for High-Risk (Metastatic) Ewing Sarcoma2022 | Second Faculty of Medicine
- Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed multiple myeloma patients: subanalysis of the phase 3 VISTA study2011 | First Faculty of Medicine
- Persistent Overall Survival Benefit and No Increased Risk of Second Malignancies With Bortezomib-Melphalan-Prednisone Versus Melphalan-Prednisone in Patients With Previously Untreated Multiple Myeloma2013 | First Faculty of Medicine
- Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial2010 | First Faculty of Medicine
- Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated MyelomaPublication without faculty affiliation
- Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial2017 | Second Faculty of Medicine
- Melphalan 140 mg/m(2) or 200 mg/m(2) for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party2018 | Publication without faculty affiliation
- Salvage treatment with upfront melphalan 100 mg/m(2) and consolidation with novel drugs for fulminant progression of multiple myeloma2010 | First Faculty of Medicine
- Continuous lenalidomide treatment for newly diagnosed multiple myeloma2012 | First Faculty of Medicine
- MMY-3002: A Phase 3 Study Comparing Bortezomib-Melphalan-Prednisone (VMP) with Melphalan-Prednisone (MP) in Newly Diagnosed Multiple MyelomaPublication without faculty affiliation
- Reduced-Intensity Conditioning With Fludarabine and Busulfan Versus Fludarabine and Melphalan for Patients With Acute Myeloid Leukemia: A Report From the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation2015 | Publication without faculty affiliation
- Prospective, Randomized Comparison between Double Transplantation (T) with Melphalan (200 mg/m2) and Triple T with Intermediate Dose Melphalan (100 mg/m2) in Patients with Multiple Myeloma (An Interim Analysis)Publication without faculty affiliation
- Research Report University Hospital clinical trial AC-004-EUPublication without faculty affiliation
- Oral cryotherapy can significantly reduce oral mucositis but not acute GVHD incidence in Flu/Mel conditioning allo-SCT2012 | Central Library of Charles University
- Prospective, Randomized Comparison Between Double Transplantation With Melphalan (200 mg/m) And Triple Trnasplantation with Intermediate Dose Melphalan (100 mg/m) in Patiens With Multiple Meloma followed by Maintenance treatment with interferon or interferon plus prednisolone (An Interim Analysis)Publication without faculty affiliation
- A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma2018 | First Faculty of Medicine
- Cytostatic Hyperthermic Isolated Limb Perfusion (HILP) in VFN (General Faculty Hospital in Prague)2011 | First Faculty of Medicine
- Thalidomide-dexamethasone versus melphalan-prednisolone as first line treatment in elderly patients with multiple myeloma: Second interim analysisPublication without faculty affiliation
- Thalidomide-Dexamethasone vs. Melphalan-Prednisone as First Line Treatment and Thalidomide-Interferon vs. Interferon Maintenance Therapy in Elderly Patients with Multiple MyelomaPublication without faculty affiliation
- Tasonermin as a part of isolated limb perfusion procedure2011 | First Faculty of Medicine
- Final report of University Hospital Hradec Kralove to the clinical trial protocol no. 54767414MMY3007Publication without faculty affiliation